Enovis CORP
No SEC Form 4 filings for $ENOV in the last 30 days.
Enovis CORP (ENOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document Enovis Announces Second Quarter 2026 Results • Second-quarter sales growth of 3% on a reported basis, 5% organic • Second-quarter Reconstructive sales growth of 8% on a reported basis, 6% organic • Reaffirmed full-year 202
Enovis (NYSE: ENOV) is set to report Q2 earnings Thursday. The company previously reported Q1 revenue of $589.2 million, up 5.4% year on year, and beat EPS and revenue expectations. For Q2, analysts expect revenue growth of 3.1% y/y. Enovis shares are up 18.5% over the past month, with an average analyst price target of $41.58 versus $30.68.
UBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ENOV (Enovis CORP). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ENOV coverage spans insider activity, earnings and technology.
Guidance reaffirmation plus modest organic growth supports the base case, but investors may focus on Recon strength versus P&R softness and margin/FCF conversion durability.
The piece is a pre-earnings setup, not a new earnings print. The main tradable input is the stated consensus trajectory versus prior-year growth and the company’s recent revenue miss pattern.
Initiation plus a defined target may support incremental demand for ENOV, especially if investors trade on coverage changes.
The U.S. product launch is a near-term demand and adoption catalyst for Enovis’s Companion Animal Health segment.
Product launch should support Companion Animal Health revenue visibility, but the article provides no financial targets or adoption metrics.
alphai scores every news story that mentions ENOV with an AI model for sentiment and relevance, and aggregates insider trades from Enovis CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Enovis CORP (ENOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document Enovis Announces Second Quarter 2026 Results • Second-quarter sales growth of 3% on a reported basis, 5% organic • Second-quarter Reconstructive sales growth of 8% on a reported basis, 6% organic • Reaffirmed full-year 202
6 min readEnovis (NYSE: ENOV) is set to report Q2 earnings Thursday. The company previously reported Q1 revenue of $589.2 million, up 5.4% year on year, and beat EPS and revenue expectations. For Q2, analysts expect revenue growth of 3.1% y/y. Enovis shares are up 18.5% over the past month, with an average analyst price target of $41.58 versus $30.68.
4 min readUBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.
4 min readEnovis (NYSE: ENOV) shares rose about 3.6% after the company said it launched CT-RevitL, a veterinary laser therapy system, in the U.S. Enovis said the photobiomodulation device targets pain management and healing and is available immediately, with international plans later. After the move, shares traded around $26.48.
4 min readEnovis (NYSE: ENOV) said its Companion Animal Health unit launched CT-RevitL, a next-generation veterinary photobiomodulation laser therapy system, in the U.S. The company says it uses COMPASS technology for calibrated dosing to reduce treatment variability. CT-RevitL is available starting July 13, 2026, with international rollout planned later.
3 min readBiotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.
6 min readEnovis (ENOV) shares rose about 15% after CMS reversed previously announced reimbursement cuts affecting the company’s non-invasive bone growth stimulators, according to reports. The move followed a prior 12% drop and broader healthcare strength after a soft June jobs report. The article cites Enovis’s prior quarter results and a 2026 adjusted EPS forecast of $3.52–$3.73.
3 min readEngert Oliver (Chief Administrative Officer) purchased 1,000 shares of Enovis CORP (ENOV) at $20.92 on 2026-06-15.
2 min readEngert Oliver (Chief Administrative Officer) purchased 1,200 shares of Enovis CORP (ENOV) at an average of $21.62 ($20.99–$21.75) across 2 trades on 2026-06-11.
1 min readEngert Oliver (Chief Administrative Officer) purchased 1,000 shares of Enovis CORP (ENOV) at $23.00 on 2026-06-10.
1 min read
